← Back to patent-cliff list
CAS 144588-13-6
N-(9-((2R,3R,4S,5R)-3-hydroxy-4-(trityloxy)-5-((trityloxy)methyl)tetrahydrofuran-2-yl)-6-(4-nitrophenethoxy)-9H-purin-2-yl)acetamide
Codes: [18F]F-AraG-001
Application context (from source-drug indications)
Alzheimer's disease[18F]F-AraGRenal cell carcinoma[18F]F-AraGSolid tumour[18F]F-AraGNon-small cell lung cancer[18F]F-AraGCOVID-19[18F]F-AraGMelanoma[18F]F-AraG
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| [18F]F-AraG | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
[18F]F-AraG→N-(9-((2R,3R,4S,5R)-3-hydroxy-4-(trityloxy)-5-((trityloxy)methyl)tetrahydrofuran-2-yl)-6-(4-nitrophenethoxy)-9H-purin-2-yl)acetamide→(2R,3R,4R,5R)-2-(2-acetamido-6-(4-nitrophenethoxy)-9H-purin-9-yl)-4-(trityloxy)-5-((trityloxy)methyl)tetrahydrofuran-3-yl trifluoromethanesulfonate→[18F]F-AraG-003
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.